Abstract
EGFR tyrosine kinase inhibitors cause dramatic responses in EGFR-mutant lung cancer, but resistance universally develops. The involvement of beta-cate......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
